The outcome of whole-body FDG-PET examination predicts the future of patients with diffuse large-cell lymphoma in the use of both intermediary staging and at the end of standard chemotherapy

Česká verzia

Authors: M. Trněný ¹; O. Bělohlávek ²; J. Kořen ¹; R. Pytlík ¹; J. Šálková ¹; P. Klener ¹
Authors place of work: I. interní klinika 1. lékařské fakulty UK a VFN Praha, přednosta prof. MUDr. Pavel Klener, DrSc. ¹; Oddělení nukleární medicíny Nemocnice Na Homolce, Praha, přednosta doc. MUDr. Otakar Bělohlávek, CSc. ²
Published in the journal: Vnitř Lék 2007; 53(9): 936-941
Category: Original Contributions

Summary

Aim:
Response to the therapy is one of the most valuable prognostic factors. The response evaluation is performed by computer tomography as a standard tool. The introduction of FDG-PET whole body imaging allows to discriminate viable tumor and fibrotic changes in structural abnormalities.

Methods:
We have performed retrospective analysis of 96 patients with diagnosis of diffuse large B-cell lymphoma (1999-2004) who were treated by anthracyclin based chemotherapy and FDG-PET was performed as a part of intermediate restaging (after 2nd-4th cycle, 69 patients) or/and at the end of standard chemotherapy (68 patients).

Results:
The progression free survival (PFS) and overall survival (OS) at 3 years were the endpoints. Median follow up was 30 months. The PFS and OS resp. for PET negative pts at intermediate restaging was 81.7 % and 97.6 % compared to the 50.5 % and 71.5 % resp. for PET positive patients. The relapse risk and death risk for PET positive patients was 4.8 and 6.4 resp. The PFS and OS resp. for PET negative pts at the end of chemotherapy was 81.7 % and 94.7 % resp. compared to the 29.4 % (p < 0.0001) and 57.5 % (p < 0.0001) resp. for PET positive patients. The relapse risk and death risk for PET positive patients was 7.0 and 12.9 resp. Predictive value of PET at intermediate as well at the end restaging was observed in IPI low group as well IPI high risk subgroups for both PFS and OS, except OS in high risk subgroup at intermediate restaging.

Conslusion:
The current analysis confirms predictive PET value for patients with DLBCL at intermediate as well at the end restaging. The question if and how to use the PET findings for tailoreing of therapy remains to be answered in prospective trials.

Keywords:
FDG-PET - lymphoma - DLBCL - prognosis - predictive value

Zdroje

1. Becherer A, Mitterbauer M, Jaeger U et al. Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation. Leukemia 2002; 16: 260-267.

2. Cheson BD, Horning SJ, Coiffier B et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244.

3. Elstrom R, Guan L, Baker G et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood 2003; 101: 3875-3876.

4. Ha CS, Choe JG, Kong JS et al. Agreement rates among single photon emission computed tomography using gallium-67, computed axial tomography and lymphangiography for Hodgkin disease and correlation of image findings with clinical outcome. Cancer 2000; 89: 1371-1379.

5. Haioun C, Itti E, Rahmouni A et al. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 2005; 106: 1376-1381.

6. Haw R, Sawka CA, Franssen E et al. Significance of a partial or slow response to front-line chemotherapy in the management of intermediate-grade or high-grade non-Hodgkin's lymphoma: a literature review. Journal of Clinical Oncology 1994; 12: 1074-1084.

7. Israel O, Mor M, Epelbaum R et al. Clinical pretreatment risk factors and Ga-67 scintigraphy early during treatment for prediction of outcome of patients with aggressive non-Hodgkin lymphoma. Cancer 2002; 94: 873-878.

8. Janicek M, Kaplan W, Neuberg D et al. Early restaging gallium scans predict outcome in poor- prognosis patients with aggressive non-Hodgkin's lymphoma treated with high- dose CHOP chemotherapy. J Clin Oncol 1997; 15: 1631-1637.

9. Jerusalem G, Beguin Y, Fassotte MF et al. Whole-body positron emission tomography using 18F- fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 1999; 94: 429-433.

10. Jerusalem G, Beguin Y, Fassotte MF et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease. Haematologica 2001; 86: 266-273.

11. Juweid ME, Wiseman GA, Vose JM et al. Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol 2005; 23: 4652-4661.

12. Shipp MA, Harrington DP, Anderson JR et al. A Predictive Model for Aggressive Non-Hodgkins Lymphoma. N Engl J Med 1993; 329: 987-994.

13. Slaby J, Belohlavek O, Taborska K et al. Predictive features of positron emission tomography after two cycles of induction therapy in malignant lymphoma. Cas Lek Cesk 2002; 141: 312-315.

14. Slaby J, Belohlavek O, Trneny M et al. Positron emission tomography (PET) in patients with malignant lymphomas - indications for the method as presented in case reports. Vnitr Lek 2001; 47(Suppl 1): 4-7.

15. Spaepen K, Stroobants S, Dupont P et al. Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? Br J Haematol 2001; 115: 272-278.

16. Spaepen K, Stroobants S, Dupont P et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 2001; 19: 414-419.

17. Trneny M, Jaeger U, Belohlavek O et al. Early Whole Body F18-FDG Positron Emission Tomography (PET) Restaging Has Significant Prognostic Impact in Diffuse Large Cell Lymphomas (DLCL-B) and Other Aggressive Lymphomas. Blood 2002; 100: 768a.

18. Verdonck LF, van Putten WL, Hagenbeek A et al. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma [see comments]. N Engl J Med 1995; 332: 1045-1051.

19. Weihrauch MR, Re D, Scheidhauer K et al. Thoracic positron emission tomography using 18F- fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood 2001; 98: 2930-2934.